G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Business Development Leader Anesthesia

Full-TimePosted on 10/21/2026
No salary listed
Expert
Bachelor's
Remote in Germany
RemoteHome-based from any location within Germany; regular business travel within Germany.
Sales & Account ManagementSales Operations

About the job

Requirements
  • A successfully completed degree in business studies, medical technology, health management, or a comparable field.
  • Substantial experience in sales, business development, or commercial management, ideally in healthcare or medical technology.
  • Demonstrated success developing growth businesses and implementing commercial strategies that produce measurable business results.
  • Substantial experience managing complex sales processes, strategic accounts, and major opportunities.
  • Experience in pricing, negotiations, tenders, and deal management, particularly in competitive business situations.
  • Good understanding of the German healthcare market, relevant market mechanisms, purchasing structures, and clinical decision-making processes.
  • Strong analytical and strategic capabilities, with a strong customer, growth, and execution orientation.
  • Interest in helping sales teams improve through coaching, constructive challenge, and commercial expertise, without direct leadership responsibility.
  • Strong communication, facilitation, and influencing abilities, and the ability to align local and international stakeholders around shared goals.
  • Ability to quickly understand complex market, customer, and business situations and translate them into clear priorities and actionable measures.
  • High initiative, a drive to shape outcomes, entrepreneurial thinking, and the ability to independently advance topics with strong execution.
  • Willingness to travel regularly within Germany.
  • Fluent German and English, spoken and written.
Responsibilities
  • Develop the commercial growth agenda for the anesthesia business with the Commercial Leader Acute Care and drive its consistent implementation within the sales organization.
  • Act as a commercial business partner to the anesthesia sales team, providing targeted support on strategic accounts, key opportunities, and complex business situations.
  • Establish funnel rigor and structured business and opportunity reviews to continuously improve transparency, forecast accuracy, early risk assessment, and commercial execution.
  • Actively support strategic opportunities, develop deal and account strategies, and drive their execution with the responsible sales team through customer decision-making.
  • Further develop pricing strategy, deal steering, and tender excellence to strengthen the quality, competitiveness, and success prospects of strategic proposals.
  • Analyze market, customer, and competitor developments; identify relevant growth opportunities; and derive concrete commercial initiatives and actions.
  • Support the sales organization through coaching, constructive challenge, and commercial expertise on account, opportunity, and negotiation strategies.
  • Work closely with the Anesthesia Segment Leader to align commercial strategy, clinical value proposition, key opinion leader engagement, and clinical and medical market strategy.
  • Support the successful commercialization of new products and solutions with sales and segment leadership, accelerate launches, and advance relevant growth initiatives.
  • Conduct regular business reviews with international anesthesia leadership, present the development of the German business transparently, align strategic priorities, and advance their implementation in the German market.
  • Actively support international growth initiatives and translate them into effective local strategy and execution with the Commercial Leader, segment leadership, and sales.
  • Work closely with Marketing, Applications, Service, Finance, Operations, and regional and international stakeholders to implement commercial priorities across functions.
Desired Qualifications
  • Experience in sales, business development, or commercial management in healthcare or medical technology.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Yahoo Finance
Oct 23rd, 2026
Cash-rich stocks: Clean Harbors worth watching, UPS and GE HealthCare best avoided

StockStory has named one cash-generating stock worth a closer look and two it would avoid, arguing that strong cash flow does not always mean strong returns. Clean Harbors (NYSE:CLH) is the pick. Its revenue grew 13.5% a year over five years, and earnings per share rose 21.6% a year, helped by share buybacks. Its free cash flow margin is 8.8%, up 5.9 percentage points over five years. The shares trade at $320.91, or 30.7x forward earnings. StockStory would steer clear of United Parcel Service (NYSE:UPS) and GE HealthCare (NASDAQ:GEHC). UPS sales were flat over five years while earnings per share fell 8.4% a year. GE HealthCare faces projected sales growth of 4.4% and a 1.7-point drop in adjusted operating margin.

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.